Viracta Therapeutics, Inc. Nasdaq
Equities
US92765F1084
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.791 USD | -95.75% | 0.00% | 0.00% |
04:42pm | Viracta Therapeutics Appoints Michael Faerm CFO | MT |
May. 09 | Viracta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe1st Jan change | Capi. | |
---|---|---|
+28.09% | 48.16B | |
-0.11% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.90% | 25.59B | |
-22.73% | 18.96B | |
+8.51% | 12.92B | |
+29.81% | 12.03B | |
-1.90% | 11.77B |
- Stock Market
- Equities
- VIRX Stock
- Stock
- News Viracta Therapeutics, Inc.
- Transcript : Sunesis Pharmaceuticals, Inc., Q2 2017 Earnings Call, Jul 27, 2017